Substance Misuse and the Older Offender.

Substance misuse is prevalent among older adults involved in the criminal justice system. The different classes of older offenders, primarily defined as individuals 50 years and older, as well as their offending behaviors vary in their association with substance misuse. Most prison health care systems do not adequately integrate substance use services. Screening for and treatment of substance misuse should be part of comprehensive mental health programs tailored to older offenders. This article reviews different types of offenses among older offenders, their association with substance misuse, and available treatment services.

Lebanese People Living with HIV: Psychiatric Co-morbidities and Psycho-Social Environment.

Data are lacking on the psychiatric and psycho-social profiles of Middle-Eastern people living with HIV (PLHIV). Our study aimed to establish the prevalence and correlates of mental illness in a sample of Lebanese PLHIV, and to delineate their socio-cultural reality. PLHIV, either attending a private ID clinic or a non-governmental organization, were interviewed. A total of 94 patients were included. Sixty-nine (73.4%) were found to have at least one psychiatric disorder. Only nine participants were currently receiving psychotropic medications. The most common diagnosis was major depression, occurring in half of the subjects. Homosexual or bisexual orientation predicted the presence of a current depression (p = 0.024), and ART status was negatively associated with current depression (p = 0.028). The rate of psychiatric disorders is clearly higher than that of the general population. PLHIV with a homosexual or bisexual orientation face a double stigma, perhaps making them more vulnerable to depression. Our findings need to be replicated in larger studies with more representative samples.

Episode of mixed mood with psychotic features secondary to Binswanger disease: a case report with a literature review.

Neurodegenerative and mood disorders in the geriatric population might exhibit interchangeable cognitive and behavioural symptoms. This overlap in presentation might raise a diagnostic challenge for psychiatrists evaluating elderly patients who are presenting with such symptoms. Additionally, there is limited data published about early psychiatric manifestations of neurodegenerative disorders in the elderly. We report a case of a 71-year-old with a history of refractory depressive disorder and multiple cardiovascular risk factors presenting with verbalisation of suicidal and homicidal intent as well as mixed mood and psychotic symptoms. The patient was diagnosed with Binswanger's disease (BD). We also provide a literature review of challenging early psychiatric presentations of neurocognitive disorders and a summary of similar cases to help facilitate diagnosis of BD cases in future.

Mental health research in response to the COVID-19, Ebola, and H1N1 outbreaks: A comparative bibliometric analysis.

INTRODUCTION: Both the COVID-19 pandemic and its management have had a negative impact on mental health worldwide. There is a growing body of research on mental health as it relates to the pandemic. The objective of this study is to use bibliometric analyses to assess the mental health research output related to the COVID-19 pandemic and compare it to that of the West Africa Ebola and H1N1 outbreaks. METHODOLOGY: We performed comprehensive searches in Embase, PubMed, and Scopus databases, and included all types of documents related to the three outbreaks published since the respective beginnings up to August 26, 2020. RESULTS: Despite the shorter time since the beginning of the COVID-19 pandemic, relative to Ebola and H1N1, we found a much greater number of mental health documents related to COVID-19 (n = 3070) compared to the two other outbreaks (127 for Ebola and 327 for H1N1). The proportion of documents in the top 10% journals was 31% for COVID-19, 24% for Ebola, and 40% for H1N1. Authors affiliated with institutions located in high-income countries published or contributed to 79% of all documents followed by authors from upper-middle-income countries (23%), lower-middle-income countries (10%), and low-income countries (2%). Approximately 19% of the documents reported receiving funding and 23% were the product of international collaboration. CONCLUSION: Mental health research output is already greater for COVID-19 compared to Ebola and H1N1 combined. A minority of documents reported funding, was the product of international collaboration, or was published by authors located in low-income countries during the three outbreaks in general, and the COVID-19 pandemic in particular.

Selective serotonin reuptake inhibitors and Alzheimer's disease.

Given the failure to develop disease-modifying therapies for Alzheimer's disease (AD), strategies aiming at preventing or delaying the onset of the disease are being prioritized. While the debate regarding whether depression is an etiological risk factor or a prodrome of AD rages on, a key determining factor may be the timing of depression onset in older adults. There is increasing evidence that untreated early-onset depression is a risk factor and that late-onset depression may be a catalyst of cognitive decline. Data from animal studies have shown a beneficial impact of selective serotonin reuptake inhibitors on pathophysiological biomarkers of AD including amyloid burden, tau deposits and neurogenesis. In humans, studies focusing on subjects with a prior history of depression also showed a delay in the onset of AD in those treated with most selective serotonin reuptake inhibitors. Paroxetine, which has strong anticholinergic properties, was associated with increased mortality and mixed effects on amyloid and tau deposits in mice, as well as increased odds of developing AD in humans. Although most of the data regarding selective serotonin reuptake inhibitors is promising, findings should be interpreted cautiously because of notable methodological heterogeneity between studies. There is thus a need to conduct large scale randomized controlled trials with long follow up periods to clarify the dose-effect relationship of specific serotonergic antidepressants on AD prevention.